What does the evidence show about Humanin's effects?

Read Off Label rates the evidence for Humanin as Preclinical and the benefit magnitude as unknown / varies, producing an overall grade of C+ (5.3/10). Declines ~60-70% from age 20 to 80 in humans.

What safety findings are reported for Humanin?

Humanin has a low risk profile in the database. Low (limited safety data) Legal status: Research chemical.

What doses or routes are reported for Humanin?

No standard clinical dose; usually studied 0.5-2 mg/day in research This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.

Rankings / Longevity — Peptides

Humanin

Longevity · Mitochondrial-derived peptide

Tier C+

Reviewed by Read Off Label · Last reviewed Jun 8, 2026 · How we grade

peptideigf-1mitochondrialresearch-only

5.3 / 10

Tier C+

Ev 2 Bn 5 Sf 9

Bottom line

Read Off Label grades Humanin as C+ (5.3/10) based on preclinical evidence, unknown / varies benefit magnitude, and a low-risk safety profile.

Declines ~60-70% from age 20 to 80 in humans.

Studied, labeled, or reported-use context: No standard clinical dose; usually studied 0. — Research chemical; not individualized guidance.

What the evidence says

Declines ~60-70% from age 20 to 80 in humans. Elevated in centenarians and their offspring. Preclinical: neuroprotective in Alzheimer's models. No human RCTs with hard endpoints — mostly observational biomarker work.

Mechanism

24-amino acid peptide from 16S rRNA; cytoprotective — blocks Bax-induced apoptosis; associated with insulin sensitivity and IGF-1 signaling; declines with age

Studied, labeled, or reported dose & route

No standard clinical dose; usually studied 0.5-2 mg/day in research

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Humanin's effects?: Read Off Label rates the evidence for Humanin as Preclinical and the benefit magnitude as unknown / varies, producing an overall grade of C+ (5.3/10). Declines ~60-70% from age 20 to 80 in humans.
What safety findings are reported for Humanin?: Humanin has a low risk profile in the database. Low (limited safety data) Legal status: Research chemical.
What doses or routes are reported for Humanin?: No standard clinical dose; usually studied 0.5-2 mg/day in research This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Humanin work?: 24-amino acid peptide from 16S rRNA; cytoprotective — blocks Bax-induced apoptosis; associated with insulin sensitivity and IGF-1 signaling; declines with age

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.